Department of Cardiovascular Disease, Mayo Clinic, Rochester, MN, USA; Division of Cardiology, Kosin University Gospel Hospital, Busan, Republic of Korea.
Department of Cardiovascular Disease, Mayo Clinic, Rochester, MN, USA.
Int J Cardiol. 2018 Sep 15;267:22-27. doi: 10.1016/j.ijcard.2018.04.139.
Takotsubo syndrome is a unique transient cardiomyopathy. The pathogenesis, management, and long-term prognosis of Takotsubo syndrome are incompletely understood. The study was designed to evaluate the natural history and determinants of outcomes in patients with Takotsubo syndrome patients.
We analyzed 265 patients in the Mayo Clinic Takotsubo syndrome registry for clinical presentation, treatment, and long-term outcomes with a focus on identifying prognostic factors for mortality and recurrence.
95% of patients were women with a mean age of 70 ± 11.8 years. Among 257 patients discharged alive, there were 89 (34.6%) deaths, 18 (6.8%) non-fatal myocardial infarction, 12 (4.7%) cerebrovascular accidents and 23 (8.9%) re-hospitalization for heart failure over a mean follow-up of 5.8 ± 3.6 years. Only 4 (5%) patients died from cardiac causes. Cancer was the single leading cause of death. Overall 1-year survival rate was 94.2%. Independent prognostic predictors of mortality were a history of cancer (HR 2.004, 1.334-3.012, p = 0.004), physical stress as precipitating factors (HR 1.882, 1.256-2.822, p = 0.012), history of depression (HR 1.622, 1.085-2.425, p = 0.009) and increased age (HR 1.059, 1.037-1.081, p < 0.001) after multivariate analysis. Beta-blockers and ACE inhibitors at discharge were not significant predictors. There were 24 (9.1%) recurrences during follow-up, but there were no significant differences in medical therapy compared to patients without recurrence.
The high mortality rate is related to non-cardiac co-morbidities such as cancer. Additional determinants include physical stressors, increased age, and history of depression. Use of beta-blockers and ACE inhibitors did not affect development, prognosis or recurrence.
Takotsubo 综合征是一种独特的短暂性心肌病。Takotsubo 综合征的发病机制、治疗和长期预后尚不完全清楚。本研究旨在评估 Takotsubo 综合征患者的自然病史和结局决定因素,重点是确定死亡率和复发的预测因素。
我们分析了梅奥诊所 Takotsubo 综合征注册中心的 265 例患者的临床表现、治疗和长期结局,重点是确定死亡率和复发的预测因素。
95%的患者为女性,平均年龄 70±11.8 岁。257 例存活出院的患者中,89 例(34.6%)死亡,18 例(6.8%)非致命性心肌梗死,12 例(4.7%)脑血管意外,23 例(8.9%)因心力衰竭再住院,平均随访 5.8±3.6 年。只有 4(5%)例患者死于心脏原因。癌症是死亡的唯一主要原因。总体 1 年生存率为 94.2%。死亡率的独立预测因素是癌症史(HR 2.004,1.334-3.012,p=0.004)、体力应激为诱发因素(HR 1.882,1.256-2.822,p=0.012)、抑郁症史(HR 1.622,1.085-2.425,p=0.009)和年龄增加(HR 1.059,1.037-1.081,p<0.001)。多因素分析后,β受体阻滞剂和 ACE 抑制剂出院时不是显著预测因素。随访期间有 24 例(9.1%)复发,但与无复发患者相比,药物治疗无显著差异。
高死亡率与癌症等非心脏合并症有关。其他决定因素包括体力应激、年龄增加和抑郁史。β受体阻滞剂和 ACE 抑制剂的使用并未影响疾病的发展、预后或复发。